DUBLIN, May 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Alpha-1 Antitrypsin Drugs Market 2016-2020" report to their offering.
The global alpha-1 antitrypsin drugs market to grow at a CAGR of 35.42% during the period 2016-2020.
Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Increased awareness about therapy is helping market growth. Alpha-1 antitrypsin deficiency (AATD) is a common yet under-recognized condition. The individuals do not recognize the symptoms, need for diagnosis, and the potentially life-threatening consequences of alpha-1 antitrypsin, thus demonstrating the need for increased awareness. Many charitable trusts and organizations are engaged in spreading awareness.
According to the report, a key driver is the improved diagnosis of AATD. AATD is difficult to diagnose in the majority of cases. The Alpha-1 Foundation reports that around 3% of all people who have diagnosed with COPD may have undetected AATD. The condition is misdiagnosed in most of the cases as asthma, smoking-related COPD, bronchitis, bronchiectasis, or other pulmonary conditions. These underlying conditions may confuse the clinical picture and thus lead to the difficulty in diagnosis.
However, awareness programs conducted by various organizations worldwide will help in recognizing and differentiating the condition from other diseases. For example, the Alpha-1 Foundation conducts support programs which include Alpha-1 Kids, Genetic Counselling Program, Caregivers Support Group, and education days at different locations throughout the US and an annual National Education Conference.
Further, the report states that limited plasma fractionation capacity could hinder market growth.
- Baxter International - CSL Behring - Grifols - Kamada
Other prominent vendors
- Abeona Therapeutics - Alnylam Pharmaceuticals - Applied Genetic Technologies - Arrowhead Research - Baxalta - Biogen - Chiesi - Curaxys - Laboratoire français du Fractionnement et des Biotechnologies - ProBioGen - ProMetic Life Sciences
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Overview: Alpha-1 antitrypsin deficiency
Part 06: Overview: Alpha-1 antitrypsin drugs
Part 07: Pipeline analysis
Part 08: Market landscape
Part 09: Market segmentation by route of administration
Part 10: Geographical segmentation
Part 11: Market drivers
Part 12: Impact of drivers
Part 13: Market challenges
Part 14: Impact of drivers and challenges
Part 15: Market trends
Part 16: Vendor landscape
Part 17: Appendix
For more information visit http://www.researchandmarkets.com/research/rcsj9w/global_alpha1
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-alpha-1-antitrypsin-drugs-market-2016-2020---key-vendors-are-baxter-international-csl-behring-grifols--kamada-300267804.html
SOURCE Research and Markets